Prostate Cancer Immunotherapy Development in Prostate Specific Antigen Transgenic Mice
Abstract
Our research is focused on the development of a PSA directed immunotherapy for prostate cancer. Through repetition of the experiments with additional controls, we confirmed our conclusion of last year that PSA can serve as a tumor rejection marker in the PSA transgenic mouse in spite of the potential tolerance to the PSA protein due to its self-status. Vaccination with a PSA expressing human tumor cell line elicited a specific anti-PSA response that protected mice from a challenge of PSA/OM-2 but not the control vector/OM-2 cell line. We identified PSA peptides that are immunogenic in the human HLA-A*0201 haplotype. Of nine candidate peptides five have been proven to be immunogenic in the HLA-A2Dd transgenic mouse after vaccination with peptide pulsed dendritic cells. These five peptides were further characterized with binding as says to reveal that four were exclusively bound by the A2 MHC molecule and one by the murine H-2D(sup b) MHC molecule. Individually, all five peptides were shown to be efficacious in inducing an anti-PSA immune response capable of protecting 33-60% of A2Dd transgenic mice challenged with the tumor cell line, PSA/EL4A2Kb. The results of these experiments allow us to continue to pursue an anti-PSA directed prostate cancer immunotherapy.
Document Details
- Document Type
- Technical Report
- Publication Date
- Mar 01, 2001
- Accession Number
- ADA394198
Entities
People
- W. M. Kast
Organizations
- Loyola University New Orleans